- Press Release -

Rockville, Md. The global prostate cancer diagnostics market is set to grow from US$ 823.5 Mn in 2017 to more than US$ 1 Bn by 2022, a 5.3% CAGR that Fact.MR links to the rise of diagnosis-led treatment. As newer therapies are built around the diagnostic approach, testing is becoming central to delivering better outcomes at lower cost.

PSA testing leads by type, hospital-associated labs handle the largest share of work, and North America carries the market. Clinicians increasingly weigh age, ethnicity, family history and diet, and given the sensitivity of the prostate area, patients are leaning toward non-invasive tests, which is reshaping the mix of products sold.

Tests, Settings and Regions

PSA tests remain the most widely used and post the highest CAGR, with serum-based testing evaluated alongside other cancer-specific markers to sharpen sensitivity. By setting, hospital-associated labs generate the largest revenue but grow the slowest, cancer research institutes expand fastest, and independent diagnostic laboratories rank second.

North America is the most lucrative region, with North America and Europe growing at similar rates, while Asia Pacific excluding Japan expands fastest and the Middle East and Africa stays sluggish.

Diagnosis Shapes Treatment

The market's direction is tied to how prostate cancer is managed. Technology advances, changing lifestyles and rising public and private funding for drug development are lifting demand, but the risk of overtreatment and over-diagnosis with PSA screening remains a real concern. High treatment costs and surgical risks, from blood clots to incontinence, also temper how quickly the market can grow.

Suppliers and Their Playbook

The field brings together diagnostics, pharmaceutical and genomic testing majors.

• Abbott Laboratories, AstraZeneca plc., Bayer Aktiengesellschaft, Danaher Corporation, Becton, Dickinson and Company, Foundation Medicine, Inc., Cancer Genetics, Inc., Myriad Genetics Inc., Agilent Technologies, and Biocept, Inc. are among the key players in the report.

Reading the Market for Decisions

For diagnostics firms, PSA and serum-based testing mark where to focus, alongside less invasive methods. Investors get a market with steady clinical demand. Procurement and lab teams can plan around hospital labs leading demand, PSA carrying volume, and Asia Pacific offering the fastest growth through 2022.

About the Report

Fact.MR's study covers the global prostate cancer diagnostics market for the 2017 to 2022 forecast period, with segmentation by test type, end user and region. It sizes each segment, maps the competitive field, and weighs the clinical forces shaping demand. Further detail is available in the prostate cancer diagnostics market report.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. The firm is known for its syndicated research, custom research and consulting solutions, helping clients make decisions on demand, competition, investment, procurement and future growth.